Mesoblast Limited (MESO) News

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

REVASCOR Increases Size of Left Heart Chamber and Improves Surgical Outcomes in Children with Hypoplastic Left...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form F-6 POS - Post-effective amendments for immediately effective filing

Form F-6 POS - Post-effective amendments for immediately effective filing

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Biotech Shares Soar Following Major Announcement

An Australian biotech company stole the show on Wednesday after it was announced that Blood and Marrow Transplant Clinical Trials Network (BMT...

Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023

NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Mesoblast Financial Results and Corporate Update Webcast

NEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Mesoblast ADSs Plunge Premarket on Latest FDA Rejection

By Colin Kellaher American depositary shares of Mesoblast plummeted more than 65% in premarket trading Friday after the biopharmaceutical...